Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019

TTX-030 is the first anti-CD39 therapeutic to be studied in patients

SOUTH SAN FRANCISCO, Calif., March 27, 2019 — Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced that it has begun enrolling patients in its Phase 1/1b clinical study evaluating TTX-030, a first-in-class, fully human, anti-CD39 antibody for the treatment of cancer.

The Phase 1/1b study will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of TTX-030 as a single agent, in combination with an approved anti-PD-1 immunotherapy, and in combination with standard chemotherapies in adults with advanced cancers. More information on the study is available at clinicaltrials.gov [TTX-030-001].

“Enrolling patients in our Phase 1/1b study represents an important milestone for Tizona as we translate our TTX-030 research efforts into the clinic,” said Scott Clarke, CEO of Tizona. “We believe that targeting CD39, which initiates extracellular ATP metabolism, could play an important role in addressing cancer progression and relapse.”

In addition, the first public presentation of TTX-030 pre-clinical data will be shared as a poster presentation at the American Association of Cancer Research (AACR) 2019 (#AACR2019) annual meeting in Atlanta, Georgia, March 29 – April 3.

AACR Poster Presentation Details:

Title: Targeting CD39 with a First-in-Class Inhibitory Antibody Prevents ATP Processing and Increases T-Cell Activation
Date and Time: April 3, 2019 8:00 am – 12:00 pm ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25
Session Category: Immunology
Session Title: Tumor Immune Microenvironment (Session PO. IM02.10 Section 25)
Abstract Number: 5012

About TTX-030, the Adenosine Axis, and the Tumor Microenvironment

TTX-030 is a monoclonal antibody that inhibits the activity of CD39, a cell surface enzyme that converts ATP to AMP, the first step in the generation of adenosine in the tumor microenvironment (TME). CD39 isupregulated on tumors as an immune evasion strategy, and on exhausted T cells and other suppressive cell types. By blocking the action of CD39, TTX-030 prevents the formation of immune suppressive extracellular adenosine, which otherwise inhibits effector cells in the TME. In addition to preventing the formation of adenosine, TTX-030 maintains high levels of extracellular ATP, stimulating dendritic and myeloid-derived cells necessary for both innate and adaptive immunity. 

TTX-030 is being developed in collaboration with AbbVie.

About Tizona Therapeutics, Inc. 

Tizona Therapeutics is a privately held, clinical-stage immunotherapy company committed to developing first-in-class therapeutics that deliver radical shifts in cancer treatment.  Through strategic partnerships and its own scientific expertise, Tizona applies novel human biological insights to address cancer progression and relapse by developing biotherapeutics that stimulate the immune system and counter immune suppression. In addition to TTX-030, Tizona has several preclinical product candidates targeting other pro-inflammatory and anti-inflammatory signals that regulate the immune system’s function.  For more information, visit www.tizonatx.com. 

Contact:

TizonaCorporate Communications
Cooper Communication Group 
Tara Cooper
tara@coopercommunication.com
650-303-7306